Alexander C. Egilman

543 total citations
22 papers, 290 citations indexed

About

Alexander C. Egilman is a scholar working on Economics and Econometrics, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Alexander C. Egilman has authored 22 papers receiving a total of 290 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Economics and Econometrics, 10 papers in Pharmacology and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Alexander C. Egilman's work include Pharmaceutical Economics and Policy (11 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers) and Pharmaceutical industry and healthcare (8 papers). Alexander C. Egilman is often cited by papers focused on Pharmaceutical Economics and Policy (11 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers) and Pharmaceutical industry and healthcare (8 papers). Alexander C. Egilman collaborates with scholars based in United States and Canada. Alexander C. Egilman's co-authors include Joseph S. Ross, Aaron S. Kesselheim, Benjamin N. Rome, Joshua D. Wallach, Steven Woloshin, Lisa M. Schwartz, Sanket S. Dhruva, Margaret E. McCarthy, Audrey D. Zhang and Jennifer Miller and has published in prestigious journals such as JAMA, SHILAP Revista de lepidopterología and Annals of Internal Medicine.

In The Last Decade

Alexander C. Egilman

21 papers receiving 287 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alexander C. Egilman United States 10 164 41 37 33 33 22 290
Audrey D. Zhang United States 10 145 0.9× 36 0.9× 49 1.3× 32 1.0× 50 1.5× 19 291
Kelly Plueschke Netherlands 7 140 0.9× 28 0.7× 25 0.7× 29 0.9× 20 0.6× 12 279
Gigi Hirsch United States 7 135 0.8× 37 0.9× 38 1.0× 19 0.6× 17 0.5× 15 268
G. Caleb Alexander United States 8 169 1.0× 54 1.3× 42 1.1× 26 0.8× 22 0.7× 11 391
Ashlyn Pinto Canada 5 262 1.6× 30 0.7× 22 0.6× 34 1.0× 26 0.8× 10 430
Jens Grueger United States 6 262 1.6× 25 0.6× 49 1.3× 29 0.9× 22 0.7× 16 374
Elita Poplavska Latvia 4 266 1.6× 37 0.9× 17 0.5× 36 1.1× 30 0.9× 12 435
Tiffany S. Woodworth United States 8 73 0.4× 58 1.4× 20 0.5× 28 0.8× 15 0.5× 14 367
Georgy Genov Netherlands 9 144 0.9× 26 0.6× 10 0.3× 61 1.8× 51 1.5× 14 389
Matthew Herder Canada 11 139 0.8× 93 2.3× 61 1.6× 35 1.1× 48 1.5× 55 346

Countries citing papers authored by Alexander C. Egilman

Since Specialization
Citations

This map shows the geographic impact of Alexander C. Egilman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander C. Egilman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander C. Egilman more than expected).

Fields of papers citing papers by Alexander C. Egilman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander C. Egilman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander C. Egilman. The network helps show where Alexander C. Egilman may publish in the future.

Co-authorship network of co-authors of Alexander C. Egilman

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander C. Egilman. A scholar is included among the top collaborators of Alexander C. Egilman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander C. Egilman. Alexander C. Egilman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Egilman, Alexander C., et al.. (2024). Federal Trade Commission Actions on Prescription Drugs, 2000-2022. JAMA. 331(23). 2029–2029. 2 indexed citations
2.
Egilman, Alexander C., Aaron S. Kesselheim, & Benjamin N. Rome. (2023). Estimated Medicare Part B Savings From Inflationary Rebates. JAMA. 329(1). 89–89. 2 indexed citations
3.
Rome, Benjamin N., et al.. (2023). Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022. JAMA Health Forum. 4(1). e225218–e225218. 27 indexed citations
4.
Egilman, Alexander C., Benjamin N. Rome, & Aaron S. Kesselheim. (2023). Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare. JAMA. 329(15). 1283–1283. 5 indexed citations
5.
6.
Rome, Benjamin N., Alexander C. Egilman, Neeraj G. Patel, & Aaron S. Kesselheim. (2022). Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone. Value in Health. 26(3). 370–377. 4 indexed citations
7.
Rome, Benjamin N., Alexander C. Egilman, & Aaron S. Kesselheim. (2022). Trends in Prescription Drug Launch Prices, 2008-2021. JAMA. 327(21). 2145–2145. 58 indexed citations
8.
Egilman, Alexander C., Benjamin N. Rome, Jonathan J. Darrow, et al.. (2022). Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings. JAMA Internal Medicine. 183(1). 82–82. 3 indexed citations
9.
Egilman, Alexander C., Joseph S. Ross, & Matthew Herder. (2021). Optimizing the data available via Health Canada’s clinical information portal. Canadian Medical Association Journal. 193(33). E1305–E1306. 3 indexed citations
10.
Puthumana, Jeremy, Alexander C. Egilman, Reshma Ramachandran, et al.. (2021). Early experience with the FDA’s regulatory review of novel gene therapies. BMJ evidence-based medicine. 27(4). 195–198. 3 indexed citations
11.
Egilman, Alexander C., Joshua D. Wallach, Jeremy Puthumana, et al.. (2021). Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration. Journal of General Internal Medicine. 36(10). 3281–3284.
12.
Egilman, Alexander C., Amy Kapczynski, Margaret E. McCarthy, et al.. (2021). Transparency of Regulatory Data across the European Medicines Agency, Health Canada, and US Food and Drug Administration. The Journal of Law Medicine & Ethics. 49(3). 456–485. 12 indexed citations
13.
Zhang, Audrey D., et al.. (2021). Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors. JAMA Network Open. 4(5). e215731–e215731. 13 indexed citations
14.
Wallach, Joshua D., Stylianos Serghiou, Lingzhi Chu, et al.. (2020). Evaluation of confounding in epidemiologic studies assessing alcohol consumption on the risk of ischemic heart disease. BMC Medical Research Methodology. 20(1). 64–64. 28 indexed citations
15.
Puthumana, Jeremy, Alexander C. Egilman, Audrey D. Zhang, Jason L. Schwartz, & Joseph S. Ross. (2020). Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration. JAMA Internal Medicine. 181(4). 559–559. 14 indexed citations
16.
Egilman, Alexander C., Audrey D. Zhang, Joshua D. Wallach, & Joseph S. Ross. (2019). Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors. Annals of Internal Medicine. 171(7). 521–523. 4 indexed citations
17.
Egilman, Alexander C., et al.. (2019). Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017. SHILAP Revista de lepidopterología. 4(1). 26–26. 1 indexed citations
18.
Wallach, Joshua D., et al.. (2018). Biomedical journal speed and efficiency: a cross-sectional pilot survey of author experiences. SHILAP Revista de lepidopterología. 3(1). 1–1. 19 indexed citations
19.
Wallach, Joshua D., Alexander C. Egilman, Sanket S. Dhruva, et al.. (2018). Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis. BMJ. 361. k2031–k2031. 51 indexed citations
20.
Wallach, Joshua D., Alexander C. Egilman, Joseph S. Ross, Steven Woloshin, & Lisa M. Schwartz. (2018). Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis. Journal of General Internal Medicine. 34(4). 492–495. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Audrey D. Zhang Breakdown of academic impact, for papers by Kelly Plueschke Breakdown of academic impact, for papers by Gigi Hirsch Breakdown of academic impact, for papers by G. Caleb Alexander Breakdown of academic impact, for papers by Ashlyn Pinto Breakdown of academic impact, for papers by Jens Grueger Breakdown of academic impact, for papers by Elita Poplavska Breakdown of academic impact, for papers by Tiffany S. Woodworth Breakdown of academic impact, for papers by Georgy Genov Breakdown of academic impact, for papers by Matthew Herder
Rankless by CCL
2026